Mark C. Holliday

Jul 11, 2024 | erj.ersjournals.com | Lee Hatter |Mark C. Holliday |Allie Eathorne |Ian D Pavord

FootnotesAuthor contributions: The Novel START study was designed by the authors prior to consultation with AstraZeneca. The global sponsor of the study, the Medical Research Institute of New Zealand, took overall responsibility for the study conduct, monitoring, and data management. AstraZeneca were not involved in the design, analysis, or drafting of this post hoc analysis, which was conducted and written independently by the study authors.

Apr 24, 2024 | electricity-today.com | Phill Feltham |Mark C. Holliday |Ron Clanton

Reviewing the benefits and addressing the obstacles BY RON CLANTON & MARK HOLLIDAY, KPMG LLP The outage management process has undergone remarkable changes over the last several decades. The need to respond to power outages when they occur has been around since the first lines were run from utility to customer. The outage management system (OMS) applications of today are far different from systems used just a decade ago.

Apr 12, 2024 | erj.ersjournals.com | Lee Hatter |Mark C. Holliday |Allie Eathorne |Ian D Pavord

FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.

Mar 1, 2024 | openres.ersjournals.com | Catherine A. Byrnes |O'Byrne PM |Godard PP |Mark C. Holliday

MethodsThe STep-wise Anti-inflammatory Reliever Therapy Children's Asthma Research (START CARE) study is an investigator-initiated, 52-week, multicentre, open-label, parallel group, phase III, two-sided superiority randomised controlled trial (RCT) based in New Zealand (figure 1). The Medical Research Institute of New Zealand (MRINZ) is the sponsor of the study, which is conducted with support from AstraZeneca Ltd., by both supply of randomised medications and funding of the study.